# Nancy Olivieri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11620033/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 29 papers | 5,905 citations | 236833 25 h-index | 477173 29 g-index |
| 30 all docs | 30 docs citations | 30 times ranked | 3839 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Prevention of a First Stroke by Transfusions in Children with Sickle Cell Anemia and Abnormal Results on Transcranial Doppler Ultrasonography. New England Journal of Medicine, 1998, 339, 5-11. | 13.9 | 1,699 |
| 2 | Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia. JAMA - Journal of the American Medical Association, 2003, 289, 1645. | 3.8 | 741 |
| 3 | A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood, 2006, 107, 3455-3462. | 0.6 | 636 |
| 4 | Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. Journal of Pediatrics, 1995, 126, 896-899. | 0.9 | 346 |
| 5 | Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion, 2001, 41, 1086-1092. | 0.8 | 296 |
| 6 | Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia Major. New England Journal of Medicine, 1985, 312, 1600-1603. | 13.9 | 269 |
| 7 | Stroke Prevention Trial in Sickle Cell Anemia. Contemporary Clinical Trials, 1998, 19, 110-129. | 2.0 | 228 |
| 8 | Relative response of patients with myelodysplastic syndromes and other transfusionâ€dependent anaemias to deferasirox (ICL670): a 1â€yr prospective study. European Journal of Haematology, 2008, 80, 168-176. | 1.1 | 210 |
| 9 | Bone Disease in Thalassemia: A Frequent and Still Unresolved Problem. Journal of Bone and Mineral Research, 2009, 24, 543-557. | 3.1 | 189 |
| 10 | Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. British Journal of Haematology, 2009, 146, 546-556. | 1.2 | 153 |
| 11 | Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. American Journal of Hematology, 2007, 82, 255-265. | 2.0 | 149 |
| 12 | Iron overload cardiomyopathies: New insights into an old disease. Cardiovascular Drugs and Therapy, 1994, 8, 101-110. | 1.3 | 128 |
| 13 | Molecular Analysis of the High-Hemoglobin-F Phenotype in Saudi Arabian Sickle Cell Anemia. New England Journal of Medicine, 1987, 316, 244-250. | 13.9 | 122 |
| 14 | Stroke risk in siblings with sickle cell anemia. Blood, 2003, 101, 2401-2404. | 0.6 | 98 |
| 15 | Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood, 2009, 114, 4632-4638. | 0.6 | 98 |
| 16 | Critical Comparison of Novel and Existing Methods of Compliance Assessment During a Clinical Trial of an Oral Iron Chelator. Journal of Clinical Pharmacology, 1994, 34, 944-949. | 1.0 | 79 |
| 17 | Effect of Long-term Transfusion on Growth in Children with Sickle Cell Anemia: Results of the Stop Trial. Journal of Pediatrics, 2005, 147, 244-247. | 0.9 | 78 |
| 18 | Inflammation and oxidant-stress in Â-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica, 2008, 93, 817-825. | 1.7 | 67 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Iron chelation adherence to deferoxamine and deferasirox in thalassemia. American Journal of Hematology, 2011, 86, 433-436. | 2.0 | 63 |
| 20 | Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clinical Pharmacology and Therapeutics, 1991, 50, 294-298. | 2.3 | 51 |
| 21 | Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 38. | 1.6 | 47 |
| 22 | Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity. Clinical Pharmacology and Therapeutics, 1990, 47, 478-482. | 2.3 | 30 |
| 23 | 5 Thalassaemia: clinical management. Best Practice and Research: Clinical Haematology, 1998, 11, 147-162. | 1.1 | 28 |
| 24 | Relationship between Chronic Transfusion Therapy and Body Composition in Subjects with Thalassemia. Journal of Pediatrics, 2010, 157, 641-647.e2. | 0.9 | 28 |
| 25 | Beliefs about chelation among thalassemia patients. Health and Quality of Life Outcomes, 2012, 10, 148. | 1.0 | 28 |
| 26 | Clinical use of the Medication Event Monitoring System: A new window into pediatric compliance. Clinical Pharmacology and Therapeutics, 1992, 52, 102-103. | 2.3 | 21 |
| 27 | Saudi Arabian Sickle Cell Anemia.. Annals of the New York Academy of Sciences, 1989, 565, 143-151. | 1.8 | 9 |
| 28 | HSC clinical trials controversy continues. Nature Medicine, 1999, 5, 3-3. | 15.2 | 7 |
| 29 | Increased leucocyte apoptosis in transfused Î²â€thalassaemia patients. British Journal of Haematology, 2013, 160, 399-403. | 1.2 | 7 |